Subscriptions are specific to an individual user and access to the platform requires a redemption code, which will be provided via email following verification of the purchase. This guide helps insurers comply with state regulatory requirements regarding annual audited financial reports and related correspondence.
A detailed chart includes statutory citations, filing deadlines, workpaper requirements, audit committee requirements and much more. Recently published in This handbook provides state insurance regulators with a resource guide to help them through the labyrinth of ERISA preemption analysis.
ERISA, a federal statute that establishes a comprehensive regulatory framework for employee pension benefit plans, preempts most state laws. This directory contains a complete listing of the 56 insurance departments that are members of the NAIC. The directory provides biographical and contact information for each regulator, as well as important information about key personnel, including titles, telephone numbers, Web sites and e-mail addresses.
Updated bi-annually. Comparative reports include a variety of information - including number of departmental staff, annual budgets, revenues collected, premium volume, number of insurers and producers, and number of consumer complaints filed.
Data displayed for easy reference and comparison. The purpose of the white paper is to provide a central resource for regulators and non-regulators regarding the insurance implications of home-sharing. The white paper describes common exclusions found in homeowners and dwelling policies and outlines the coverage options for home-sharing hosts and guests.
The white paper also highlights legal restrictions that may prohibit home-sharing in some areas and describes the type of coverage available by the largest home-sharing companies currently operating in the U.
This publication contributes to the goal of providing state insurance departments with an integrated approach to screening and analyzing the financial condition of insurance companies by explaining ratio calculations and providing worksheets and benchmarks that are part of the NAIC's IRIS.
Provides detailed demographic information on more than 5, Property, Life and Fraternal, Health, and Title insurers, as well as more than 17, offshore alien insurers and reinsurers included in the NAIC database.
The product is a zipped file of individual reports in comma-separated values format and is available in Account Manager upon confirmation of purchase. Each report includes a record layout to assist with downloading the files for use in a spreadsheet or database. Published semiannually.
Provides domestic company codes and names for more than 5, Property, Life and Fraternal, Health, and Title insurers, as well as more than 17, offshore alien insurers and reinsurers included in the NAIC database.
It also indicates the status of the company and provides all necessary information for completing the reinsurer-related requirements in Schedule F and Schedule S of the annual and quarterly statements.
This publication should be used to ensure that all financial filings conform to NAIC requirements. Posted semiannually. Financial Statement Data Purchase the data that is the basis of this report and manipulate it to achieve the best possible results for your research.
Form 1 focuses on the critical assumptions of morbidity and persistency while still presenting high-level loss ratio data. Form 2 focuses on the developing level of funds from the issue age premium basis and compares this to the active life reserve. Form 4 tracks life insurance and annuity products that have long-term care benefits provided by acceleration of certain benefits within these products. Form 5 requires information at the state level.
This publication combines information from the Market Conduct Examiners Handbook and the Market Analysis Handbook into one comprehensive source of reference material from the continuum of regulatory responses to potential market concerns. The goal with this publication is to help market regulators conduct uniform, standardized market analysis and market conduct examinations.
However, demand remains high for accessible content in a work-from-home environment. As a result, there is a business need to make access to online content available to customers working remotely.
This new subscription service provides access to the published version of the handbook, and Market Regulation Handbook Reference Documents will be available in Account Manager.
Modifications to the handbook will be uploaded to the OSS platform as they become available following each interim and national meeting of the Market Regulation and Consumer Affairs D Committee. Designed to serve as a compilation of the market conduct examination standards found in Chapters 20 - 32 of the Market Regulation Handbook.
Arranged and organized by chapter and area of examination, regulated entities might find this summary useful in creating an outline for internal review templates. Please note: This summary does not represent all examination standards, methodologies and areas of review that could be utilized by an insurance department.
An easy reference for identifying top writers by premium volume. Allows monitoring of increases and decreases in market share and overall level of market concentration.
The Life and Fraternal reports contain the top groups by state and countrywide for life insurance, annuity considerations and total premiums written. It identifies direct premiums earned, market share, direct claims incurred and loss ratios on a countrywide basis. A listing of the top 10 companies by state by direct premiums earned is also included in this report. Reports available since This product provides access to every NAIC model law, regulation, and guideline currently published.
By selecting this publication, it allows access to Account Manager to view state law charts related to the Model Laws. Included with every model is a state action page that cites each state's enacted model or similar legislation. Many models also include a legislative history Proceedings Citations that explains why the model was adopted and why certain provisions were included. This digital publication is now offered as three separate products, which will include the full six-volume set as well as updates that occur after the NAIC's Spring, Summer, and Fall National Meetings.
Information will be provided at the beginning of each product showing the updated material within the product. A listing of mutual funds that meet conditions in the Purposes and Procedures Manual of the NAIC, qualifying them for more favorable reserve treatment. This publication offers practical considerations about implementing a loss-cost system in workers' compensation.
Designed as a premier research tool, the Proceedings of the NAIC is the official, permanent record of all NAIC action, including model laws and regulations, as well as committee and task force minutes and reports. Published following each national meeting. Even if importation or reimportation, or both, were allowed, it is not clear how much they would reduce drug costs for U. The outcome would depend largely on 1 the countries from which drugs may be imported or reimported, and 2 the strategic responses of U.
A key question is how large a supply of drugs Canada and other approved countries would make available for export back to the United States or, in the case of generics, allow them to be imported by the United States at lower prices. The CBO has concluded that the savings would not be substantial if reimportation were limited to Canada because drug companies probably would not increase their Canadian sales enough to allow a significant propor-.
It is also possible that manufacturers could penalize countries and firms that exported products back to the United States or that imported generics and biosimilars to the U. Firms could, for example, raise the prices of drugs sold in Canada, or penalize wholesalers that reimported drugs by raising the prices of the drugs they sell to those particular wholesalers in the United States. There is anecdotal evidence of penalizing behavior on the part of U. A larger question is whether importation and reimportation would spur manufacturers to reduce their investment in research and development.
In recent years there have been numerous high-profile reports of inadequate supplies of generic drugs that have served as the standard of care for some diseases. For example, shortages have been reported for two critical cancer drugs, Doxil and Methotrexate, a medication used as backbone therapy to treat pediatric cancer Harris, ; various antibiotics, including doxycycline Stone, ; and saline bags, which are used throughout inpatient and outpatient treatment McGinley, Although the number of new drug shortages has declined since , prominent shortages exist among generic injectables and other drugs for cancer and cardiovascular conditions ASHP, a; GAO, , a , and drug shortages have been known to lead to adverse events and even increased patient morbidity and mortality Duke et al.
Shortages, threatened and actual, often result from lapses in manufacturing quality Fox et al. For example, the immediate precipitating factors behind the shortages reported since largely for infused and injectable drugs include a lack of high-quality manufacturing processes and facilities and a lack of necessary compounds and raw materials GAO, ; Pew, ; Stomberg, ; Woodcock and Wosinska, The lapses in manufacturing quality and the shortages in the of necessary or adequately manufactured raw materials that can lead to supply interruptions of certain drugs and other products regulated by the FDA are not new, but appear to be more frequently reported in recent years.
For example, in , the FDA reported that at least 81 deaths and serious injuries were thought to be linked to a. This led to the withdrawal of the product from the U. Yet, according to a recent report from the American Society of Health-System Pharmacists, the immediate causes for more than one-half of drug shortages reported in were unknown ASHP, b. In some circumstances, unexpected consumer demand or an outbreak of a rare illness can contribute to drug shortages ASPE, ; Fox et al.
In addition, a federal report noted that class-wide shortages in were likely due to a rapid and sizeable increase in the scope and volume of products produced without a corresponding increase in overall manufacturing capacity ASPE, The constrained supply of these drugs and the high costs of entry for manufacturers willing and able to produce these molecules for sale in the U.
The FDA response to periodic drug shortages has largely been to either pull or push more manufacturers into supplying U. The growing trend to outsource drug manufacturing and to source base ingredients from non-U. More recently, under the Safety and Innovation Act of , the FDA required drug manufacturers to provide early notification of any manufacturing interruptions or production changes that could lead to a supply disruption or the discontinuation of a product.
Subsequently, the FDA improved its efforts to prevent shortages by expediting application reviews and inspections, exercising enforcement discretion in relevant cases, and helping manufacturers respond to quality control issues in drug manufacturing Chen et al. Every year drugs worth billions of dollars that have been purchased by health care organizations e. Some of this waste in the system could be eliminated by changing the way drugs are packaged and labeled. For example, vials of infused drugs are often available only in a single dose size that is.
As a result, the remaining drug must be discarded when a smaller patient is treated. Because 18 of the top 20 infused cancer drugs are sold in just one or two vial sizes, 10 percent of the purchased drug amount is discarded on average Bach et al. Manufacturers propose dose sizes for marketing, and the FDA only reviews the request for safety considerations FDA, However, in Europe, where governments play a more active role than the United States does in drug pricing and distribution, many of these medicines are distributed in smaller vial sizes, reducing the potential for waste.
Many medicines are also discarded because of expiration dates Allen, Since the FDA has required drug manufacturers to provide evidence of product stability, by subjecting drugs to various environmental variables such as temperature, humidity, and light, but there are no requirements for long-term testing. Pharmacies routinely discard stocked drugs when they reach their expiration date, but many drugs, if stored properly, are stable long beyond the expiration date on the label Cantrell et al.
Department of Defense to support the maintenance of its stockpiled drugs, worth billions of dollars. In a study of different medication products, nearly 90 percent met the requirements for an extension; the average additional extension length by SLEP was 5.
Extending shelf life could not only reduce waste in the system, but also address shortages. The FDA recently posted updated expiration dates for batches of several different injectable drugs to help address ongoing critical shortages of these drugs used in critical care FDA, d. The American Medical Association and other entities have called for routinely collecting more data on long-term stability and revising expiration dates as appropriate Diven et al.
An independent organization could conduct more testing similar to that done by the FDA extension program. Information from the extension program also could be applied to properly stored medications. Drugs worth billions of dollars are discarded each year by nursing homes and other long-term care facilities when they are no longer needed by residents Allen, ; Coggins, A few states and nonprofit organizations have set up programs to collect, sort, and redistribute these unused drugs to reduce waste and costs to patients.
However, in many areas no such programs exist and in some cases are even illegal , so valuable drugs are simply discarded. A key factor affecting the affordability of health care for individuals and families is whether a patient has health insurance. After the implementation of the ACA, the number of people with health insurance increased substantially, but approximately 10 percent of the population under age 65 has no health insurance—and hence no coverage for prescription drugs.
Furthermore, not all of those with health insurance have insurance coverage for prescription drugs. This latter circumstance applies to both the under population and those on Medicare. Fee-for-service Medicare helps cover the cost of prescription drugs for people who enroll in a Part D drug plan see Figure , but enrollment is voluntary and only 42 million of the 57 million Medicare beneficiaries have Part D coverage KFF, b.
However, of the remainder, some have drug coverage through employers, the U. As of , 99 percent of covered. Recent changes in insurance design in the United States reflect the rising costs of not only drugs but all sectors of health care Consumer Reports , As the costs of health care have risen, employers and insurers have modified benefit designs as a way to keep premiums as low as possible, with the goal of balancing cost and access.
The escalating list prices of many branded drugs, especially specialty drugs and those that lack a competitor, have been a particular challenge in recent years. As a result, even among those with insurance benefits, the out-of-pocket costs for premiums, deductibles, and copays can be substantial, and the design of the coverage and cost sharing can significantly affect the financial burden arising from prescription drug spending.
Studies have found dramatic reductions in coverage generosity and shifts to percentage-based cost sharing for high-priced drugs over time Doshi et al. The specifics of pharmacy benefit design have the potential to be an important public health tool for improving patient treatment and adherence Goldman et al. The effects of high out-of-pocket spending can be significant for patients and their families. Increased cost sharing can reduce patient uptake and adherence to treatments, including specialty drugs Alexander, ; Doshi et al.
Nearly one-quarter of the Americans who participated in a survey reported that they had difficulty affording their prescription medicines. And nearly one-quarter reported that they or a family member had not filled a prescription that they had been provided, had skipped doses, or had reduced their dosage because of cost KFF, One study of commercially insured adults with chronic myelogenous leukemia found that having higher out-of-pocket costs reduced patient adherence to therapy by 42 percent and increased the discontinuation of therapy by 70 percent Dusetzina et al.
A study on primary care found that approximately 31 percent of patients did not fill their prescriptions within the first 9 months after receiving them from a doctor. Additionally, the study found that patients with higher copayment fees, recent hospitalizations, severe comorbid conditions, or some combination of these three factors were less likely to fill their prescriptions Tamblyn et al.
Various studies confirm that poor adherence leads to negative clinical outcomes and increased health care costs e. Even for insured patients, the use of prescription drugs often entails a large out-of-pocket expense because of the high coinsurance rates that often apply to expensive drugs, particularly if the patients use specialty drugs or multiple high-cost brand-name drugs.
For example, traditional Medicare currently places no upper limit on the total amount an individual may end up spending on cost sharing for Medicare-covered services. For services offered under Medicare Part B, including clinician-administered drugs, the beneficiaries or their supplemental insurance plans are responsible for 20 percent of the cost MedPAC, , and there are no catastrophic coverage limits. This can translate to hundreds or even thousands of dollars annually in out-of-pocket costs for higher-cost medications.
Individuals with employer-sponsored or other types of private health insurance also face challenges with prescription drug costs. As noted above, in response to increasing costs across all sectors of health care, insurance companies have raised deductibles, increased monthly premiums, imposed or increased copays and coinsurance, and transferred high-cost drugs to more expensive formulary tiers Claxton et al.
Among employer-sponsored plans, deductibles grew from 4 percent of cost-sharing payments in to 24 percent in ; coinsurance increased from 3 to 20 percent over that same period Cox, Private health insurance plans have been moving to three- or four-tier coinsurance or copayment structures that require a smaller degree of cost sharing for generics and a greater degree for higher-cost drugs especially when there are therapeutically equivalent options KFF, However, every plan, whether Part D or an employer-sponsored pharmacy benefit, has an exception process that permits coverage of a drug not on formulary or reduce out-of-pocket cost if a physician provides information about side effects the patient has experienced from a lower-tiered drug or offers another medical reason for switching.
As noted in Box , most large employers self-finance their health insurance contributions for their employees and hence have a direct and significant interest in controlling health care costs. The ubiquity of such plans can influence how much individuals cov-. The average coinsurance was 17 percent for first-tier drugs and 38 percent for third-tier drugs.
In addition to copayments and coinsurance, health plans can apply an additional deductible to drugs that is separate from the general annual deductible. These plans require a higher deductible than most health plans, in exchange for a lower monthly premium. High-deductible health plans require consumers to cover percent of their health care costs up to a certain amount—the deductible—at which point their insurance coverage and other cost-sharing arrangements begin.
In , nearly 30 percent of individuals in employer-sponsored plans were enrolled in a high-deductible health plan Claxton et al. Recent work has begun to explore the clinical and economic benefits of high-deductible plans in the long run Fronstin et al.
Many oral drugs used to treat complex conditions such as HIV, multiple sclerosis, rheumatoid arthritis, cancer, and hepatitis C are costly, and the increasing use of deductibles and coinsurance in the pharmacy benefit offered by insurance plans may lead to significant financial hardship for patients needing treatment.
Medicare beneficiaries are exposed to high costs in two primary ways. After enrollees reach the catastrophic coverage threshold, Medicare pays for most 80 percent of their drug costs, plans pay 15 percent, and enrollees pay 5 percent of total drug costs. Second, even patients who reach the catastrophic coverage threshold of Medicare Part D can be exposed to high costs because the threshold is not a hard cap on out-of-pocket costs.
For medications costing tens of thousands of dollars or more per year, patients can spend more out of pocket during the catastrophic phase than in the other benefit phases combined Hoadley, A recent analysis found that 3. To mitigate the concern that pharmaceutical companies might respond by simply raising their list prices, one strategy might be to increase the share of total costs that Part D plan sponsors pay in the catastrophic coverage phase of the benefit up from the current 15 percent , giving them a stronger financial incentive to negotiate larger rebates for higher-priced drugs and to take more steps to manage the use of these drugs by their enrollees, which could produce savings for enrollees, Medicare, and the plans themselves.
This practice may bring the price that patients pay for branded medications closer to—and in some cases lower than—the price of generic alternatives, but it does not change the cost to the insurer. In fact, such practices serve to increase costs to insurers and therefore, the premiums charged by the insurer. The popularity of patient assistance programs among both patients and manufacturers has increased over time Daubresse et al.
Assistance programs are delivered through a variety of mechanisms, including coupons, drug savings cards, manufacturer assistance programs provided through the drug maker , access networks that create disease-specific funds, and disease-focused foundation programs.
Support can include providing medications or payments directly to individuals. Eligibility for support from these sources varies by insurance status and income. Some types of copayment assistance are not allowed, including the use of manufacturer coupons to pay for drugs obtained through Medicare Part D benefits. While helpful in some ways, patient assistance programs encourage patients to use higher-cost branded products, since generic manufacturers do not typically offer assistance programs.
Patients with very high deductibles or with high coinsurance requirements may find it difficult to pay the out-of-pocket costs to obtain high-priced drugs. In such cases, patients may need to access assistance programs in order to offset the out-of-pocket costs of starting and adhering to therapy, regardless of their insurance status.
Each program is a unique, unregulated, private offering by a pharmaceutical company for an individual product. The application process can be onerous for patients and clinicians, with a high probability of rejection, commonly based on patient income level and insurance coverage.
There is little information available to evaluate the impact of patient assistance programs so few studies have examined the proportion of patients served, the extent of aid provided, the criteria for qualifying for aid, and the estimated financial cost to society Felder et al.
Drug manufacturers tend to use coupons to promote the use of branded expensive products when less expensive alternatives are available Dafny. One analysis estimated that copay coupons increased branded drug sales by 60 percent or more, almost entirely by reducing the sales of generic competitors, and that they had the potential to undermine the efforts of prescription drug insurance plans Dafny et al. Federal policies prohibit the use of manufacturer coupons in paying for medications paid for by Medicare Part D because it is considered a violation of anti-kickback statues and it raises costs to the government OIG, Congress created the Medicaid Drug Rebate Program MDRP , which went into effect in , resulting from the Omnibus Budget Reconciliation Act of in an attempt to address the rising cost of prescription drugs in the Medicaid program.
In the MDRP, the drug manufacturer enters into a rebate agreement with the HHS secretary in return for Medicaid coverage of all products made by this manufacturer, as well as payments for covered outpatient drugs provided through Medicare Part B.
This has essentially created an open formulary in Medicaid. Unlike most rebates for prescription drug spending, the rebates obtained through the MDRP are not negotiated, but are defined by statute. However, many components used to calculate the rebate are proprietary, and as a result, it is difficult to calculate exactly how much Medicaid spends on a particular drug.
This contributes to the lack of transparency surrounding drug pricing. Statutory rebates are set by the U. Congress and enacted into law, and there have been changes over time. States are free to negotiate supplemental rebates on top of the statutory rebates. The basic rebate calculation for single-source drugs and innovator multiple-source drugs 8 is set by statute and is set separately for non-innovator, multiple-source drugs.
For single-source and innovator multiple-source drugs, the unit rebate amount is equal to the greater of either the product of Average Manufacturer Price AMP times Statute sets different rebate percentages for certain types of single-source and innovator multiple-source drugs: clotting factors and drugs approved by the FDA exclusively for pediatric indications. For non-innovator, multiple-source drugs, the unit rebate amount is equal to the product of AMP times 0.
The rebate on innovator drugs includes an adjustment to account for price inflation; however, this adjustment is not included in the rebates for non-innovator drugs.
Department of Veterans Affairs, the U. Rebates are paid by drug manufacturers on a quarterly basis to states and are shared between the states and the federal government. Under the ACA, drugs provided in managed care settings are also eligible for rebates and as a result, states have increasingly been providing the Medicaid prescription drug benefit through managed care.
States have been left vulnerable to the high costs of branded drugs that have little competition McConnell and Chernew, Recently, Massachusetts submitted an amendment to its demonstration waiver to CMS that would allow the state to have a closed formulary. Prior to the implementation of the MDRP in , manufacturers often provided discounts on their drugs to safety net providers.
The waiver request is pending as of November Congress addressed this potential unintended effect of the MDRP with the B program, a drug discount program named after the section 10 in the law that created it Health Affairs , a. Covered entities can seek additional rebates on top of the B discount. The law instructs the HHS to enter into a pharmaceutical pricing agreement PPA with drug manufacturers as a stipulation for their drugs to be covered under Medicaid.
If a drug manufacturer signs a PPA, it agrees that the prices charged for covered outpatient drugs to covered entities will not exceed B ceiling prices as defined by statute.
Drugs included in the B program generally consist of outpatient prescription drugs and drugs administered by clinicians in an outpatient setting, excluding vaccines. HRSA administers the B program and is responsible for the oversight of various stakeholders, including covered entities and pharmaceutical companies. The ACA expanded the types of covered entities eligible to participate in the B program, including critical-access hospitals, rural referral centers, sole community hospitals, and freestanding cancer centers.
Furthermore, in , HRSA allowed B entities to sign agreements with more than one outside pharmacy—known as contract pharmacies—to provide the covered drugs. Contract pharmacies are employed by some hospitals and clinics to expand services outside of hospital walls HRSA, By design, B program participation provides qualified entities the opportunity to generate revenue from administering and dispensing prescription drugs, financed by pharmaceutical manufacturers, insurers, and paying patients Conti and Bach, The program does not require enti-.
It also does not require these entities to limit the patients who receive the discounted drugs to those who are uninsured or underinsured. These exemptions in turn influence the costs of drug therapies among fee-for-service Medicare beneficiaries and the commercially insured. Patient deductibles and coinsurance payments associated with prescription drugs reflect the reimbursement set by the insurer to the pharmacy or the clinic; these are unaffected by B discounts.
Debate about the program has intensified recently, due in part to the large number and the significant diversity of providers receiving the discounts and their safety net roles GAO, ; OIG, ; von Oehsen et al. Outpatient clinics participating in B are, by definition, serving vulnerable patient populations. In , these standalone safety-net clinics were outnumbered by hospitals, their affiliated outpatient clinics, and contract pharmacies participating in B OIG, Particular scrutiny has focused on acute care nonprofit hospitals.
In , roughly one-third of all acute-care not-for-profit hospitals in the United States qualified as covered entities under the B program Conti and Bach, , and they are thought to have accounted for approximately 48 percent of the national outpatient hospital visits Mulcahy et al.
In contrast to the clinics, acute care, nonprofit hospitals and their affiliated outpatient clinics participating in the B program are not required to demonstrate that they provide community benefits in the outpatient setting. To be eligible for B discounts, HRSA requires only that hospitals provide inpatient services to Medicaid and low-income Medicare beneficiaries to the degree that their Medicare disproportionate share patient percentage 11 exceeds the eligibility threshold of The disproportionate patient percentage is equal to the sum of the percentage of.
Evidence about the impact of B revenue on safety net and community need engagement among qualifying hospitals is largely anecdotal B Health, ; Kantarjian and Chapman, ; Wallack and Herzog, GAO conducted a cross-sectional comparison of B-qualified Medicare disproportionate share hospitals with nonB hospitals in using publicly available data from Medicare hospital cost reports GAO, The report found that B hospitals provided more uncompensated care than did nonB hospitals and also had lower profit margins than nonB hospitals, in part because they provided more uncompensated and charity care.
A more recent report found that hospitals participating in B in exhibited widely varying financial stability and safety net care provision Nikpay et al. Some B disproportionate share hospital DSH program participants operated at a substantial loss, but at least one-quarter of participants operated with a comfortable margin.
Many of the hospitals with the highest operating margins were also those that provided the least uncompensated care, while the hospitals that provided the most uncompensated care had the lowest operating margins.
Furthermore, there was little correlation between county-level uninsured rates and the adjusted DSH patient percentage. Finally, some B hospitals and clinics built large networks of contract pharmacies after HRSA released its guidance. As contract pharmacy arrangements have proliferated, especially with national chains including Walgreens, Rite Aid, CVS, and Walmart, these agreements have come under scrutiny.
They are not subject to routine independent audits like other B program providers and manufacturers. Furthermore, contract pharmacies are not required to demonstrate that they serve vulnerable populations at all, nor are they required to show that they meet the core program objectives to qualify for discounts. The report noted that covered entities using contract pharmacies do not always offer the discounted B price.
Medicare inpatient days attributable to patients eligible for both Medicare Part A and the Supplemental Security Income plus the percentage of total inpatient days attributable to patients eligible for Medicaid but not Medicare Part A. Under current statute, neither HRSA nor CMS collects information from qualifying entities or drug manufacturers regarding which drugs are being purchased through the B program, the amount of B-derived revenue generated by qualifying entities, or how revenues are used to benefit vulnerable patient populations.
Reports from several pharmaceutical manufacturers suggest that sizable proportions of national product sales 10 to 20 percent are currently subject to B discounts. GAO also analyzed spending on oncology drugs covered under Medicare Part B in , comparing hospitals that were or were not qualified to participate in the B program GAO, Part B spending on those drugs was substantially higher at B hospitals than at nonB hospitals.
Stakeholders have expressed concern that the scale of the program has increased without a subsequent correlation in resources dedicated to oversight. Of particular concern has been the strengthening of oversight by HRSA and CMS to adequately enforce existing prohibitions on diversion and duplicate discounts among covered entities and contract pharmacies GAO, Diversion is when a B drug is given to an ineligible patient or resold by the covered entity.
Under current statute, eligible patients are defined as those who receive regular medical care at covered entities or who participate in an AIDS drug-purchasing assistance program and who are not insured by Medicaid, although there are some exceptions.
While manufacturers can audit covered entities for suspected unauthorized use of B drugs, covered entities do not have any audit authority and they must petition HRSA to investigate manufacturers or turn to the judicial system when purported violations in B pricing occur; therefore, another focus of these efforts has been to strengthen oversight of possible manufacturer overcharges.
The ACA required a new dispute resolution process and greater pricing transparency by establishing a B. This change will also result in reduced out-of-pocket payments for Part B beneficiaries undergoing outpatient drug-based treatment HHS, The special protections afforded to drugs that prevent or treat rare diseases also influence their availability and may have an impact on their affordability as well.
The European Union identifies a rare disease as a condition affecting no more than 5 in 10, people Gammie et al. Fewer than 10 such industry-sponsored products entered the market in the decade preceding the act FDA, e. Over the past 5 years, orphan drug approvals have increased exponentially Evaluate Pharma, In , nearly half of the new medications approved were orphan drugs, including two that are indicated for diseases with no approved treatments FDA, e.
The program provides a number of benefits to the sponsors of FDA-designated products for rare diseases FDA, e , including an additional 7 years of market exclusivity. Participating firms also benefit from more open study protocols with fewer eligibility criteria , which are intended to increase access of affected patients to the medications, and these firms may also receive modest FDA grant support to investigate treatments for rare diseases.
The regulatory review process for orphan drugs is expedited, and clinical trials can enroll smaller numbers of patients than would otherwise be acceptable in registration trials.
The manufacturers of orphan drugs can. Furthermore, the act allows manufacturers to claim a tax credit 13 in the taxable year of up to 50 percent for expenses paid or incurred by the sponsor on human clinical trials required to obtain FDA approval FDA, c. These factors tend to substantially reduce the development costs for orphan drugs compared with what traditional drugs cost to develop HHS, However, sponsors are required to request orphan drug designation from the FDA before filing a new drug application FDA, e.
Drugs for rare diseases often have higher prices because of the small size of the eligible patient population and because there are generally few if any competitors to address what is most often a high unmet need.
Orphan drugs are also more likely to be biologics, which tend to be less susceptible to generic competition Thomson Reuters, The median cost per patient is 5. From to , orphan drug sales increased These include Vioxx, Cialis, and Botox. Hu PDF - 1. Collective links are provided in 2 or 3 Different Clouds at the end of Each Post. Fill out, securely sign, print or email your nurses notes templates form instantly with SignNow.
Both items are free. Identify common formats of the medical record. Pages: These notes are of Made Easy coaching institute, New Delhi. October 8, by Dr. If you don't see an OpenOffice Template design or category that you want, please take a moment to let us know what you are looking for. XXX X The second segment Product Code can be 3 or 4 digits in length, and it represents the product strength, dosage form, and formulation.
I really like that I can freely move the notes anywhere on top of the PDF, annotate with gesture, move annotations around, share notes across different PDF files, look up words in the dictionary, keyword search in PDF, etc. Arshad Bangash Leave a Comment. These exam notes also represented a defining moment for me as a student, because they proved to me that I was stubborn enough to write a set of exam notes even if it was a complete waste of time.
In order to ensure that user-safety is not compromised and you enjoy faster downloads, we have used trusted 3rd-party repository Nursing Notes Pdf. About Us. See image of free textbook below. Download Free Medical Notes. So we have brought all 1st-year MBBS book in pdf form. Size: B. Fun Stuff.
Feel free to contact us , be our team member to promote us and helping others. A short summary of this paper. University of Basrah. Our digital library saves in fused countries, allowing you to acquire the most less latency times to download any of our books gone this one.
File Count 1. These notes are required whenever a student or employee is expected to disappear from school or office on medical grounds. The study setting was the bed medical center of the Denver Health and Hospital Authority, an integrated, urban safety-net system. Achalasia is a medical condition that affects the way food can pass through your oesophagus into your stomach.
If you use my log sheets in your geocache, add a link to http Health and Medical Templates in OpenOffice format. Merely said, the toronto notes for medical students pvaz is universally compatible gone any devices to read. Medical Terminology cards These handouts are intended to provide at-a-glance suggestions and strategies relevant to the needs of medical students.
Tissues of the Body. July MedicoNotes is a growing online medical website which provides a set of medical services. This blog will be helpful for Medical, Dental and Paramedical students in understanding various topics which are prepared by the topmost Doctors in the medical field. Download with high speed from Google Drive.
Pharmacy student to revise the whole syllabus in minutes. Anatomy is the branch of biology concerned with the study of the structure of organisms and their parts. These Books will be useful for all students of Medicine and Surgery. Use Template. This paper. You can also find all the drug and disease information. Anatomy is a branch of natural science which deals with the structural organization of living things.
In this article, we also provide complete details of the b.
0コメント